http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113521082-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bae7cf399c53b51787e575edaf8b820 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-37 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585 |
| filingDate | 2021-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f062aa80ff0b9614459b0e2285afb408 |
| publicationDate | 2021-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113521082-A |
| titleOfInvention | Application of triptolide in preparing medicine for preventing and/or treating liver disease |
| abstract | The invention discloses the application of triptolide in the preparation of medicines for preventing and/or treating liver diseases, in particular the preparation of triptolide or a pharmaceutically acceptable salt thereof in the preparation of preventing and/or treating non-alcoholic fatty liver or liver disease applications in fibrosis. The experimental results of the present invention show that triptolide can significantly reduce the level of serum liver enzymes, and also has the effect of delaying liver steatosis, inflammation and fibrosis, and can significantly reduce the expression of fibrosis-related proteins such as α-SMA, collagen I, and fibronectin. It has a precise therapeutic effect on non-alcoholic fatty liver disease, and provides a new choice for clinical medication. |
| priorityDate | 2021-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 113.